Related Experiment Video
Updated: Jun 16, 2025
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a
Md Ridoy Hossain1, Md Mohaimenul Islam Tareq1, Partha Biswas1
1Laboratory of Pharmaceutical Biotechnology and Bioinformatics, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jessore, Bangladesh.
Insights
This study identifies key genes and molecular pathways in Huntington's disease (HD) using bioinformatics. It also proposes potential drug candidates for future HD treatment and diagnosis.
Area of Science:
- Neuroscience
- Genetics
- Bioinformatics
Background:
- Huntington's disease (HD) is a severe neurodegenerative disorder caused by CAG trinucleotide repeat expansion.
- Current understanding of HD molecular mechanisms and biomarkers is limited, hindering early diagnosis and effective treatment.
- Existing diagnostic methods for HD lack precision and accuracy.
Purpose of the Study:
- To elucidate biomarkers, pathways, and therapeutic targets in Huntington's disease molecular processes.
- To apply network-based systems biology and bioinformatics for a comprehensive analysis of HD.
- To identify potential therapeutic compounds for Huntington's disease through in silico drug design.
Main Methods:
- Analysis of gene expression profile datasets (GSE97100, GSE74201) relevant to Huntington's disease.
- Identification of differentially expressed genes (DEGs) and hub genes using protein-protein interaction (PPI) network analysis.
- Prediction of transcription factor (TF)-DEG and microRNA (miRNA)-DEG interactions, and Gene Set Enrichment Analysis (GSEA).
- In silico drug design for identifying potential therapeutic agents.
Main Results:
- 46 differentially expressed genes (DEGs) were identified in Huntington's disease.
- 10 hub genes, predominantly down-regulated, were pinpointed within the PPI network.
- Key gene ontology concepts, TF-DEG, and miRNA-DEG interactions were predicted.
- Several potential therapeutic compounds, including cortistatin A, were identified via in silico drug design.
Conclusions:
- This research provides valuable insights into the molecular underpinnings of Huntington's disease.
- The identified biomarkers and pathways can aid in the experimental validation of HD diagnosis.
- The study suggests potential therapeutic targets and compounds for future Huntington's disease treatment strategies.
Abstract:
Huntington's disease (HD) is a gradually severe neurodegenerative ailment characterised by an increase of a specific trinucleotide repeat sequence (cytosine-adenine-guanine, CAG). It is passed down as a dominant characteristic that worsens over time, creating a significant risk. Despite being monogenetic, the underlying mechanisms as well as biomarkers remain poorly understood. Furthermore, early detection of HD is challenging, and the available diagnostic procedures have low precision and accuracy. The research was conducted to provide knowledge of the biomarkers, pathways and therapeutic targets involved in the molecular processes of HD using informatic based analysis and applying network-based systems biology approaches. The gene expression profile datasets GSE97100 and GSE74201 relevant to HD were studied. As a consequence, 46 differentially expressed genes (DEGs) were identified. 10 hub genes (TPM1, EIF2S3, CCN2, ACTN1, ACTG2, CCN1, CSRP1, EIF1AX, BEX2 and TCEAL5) were further differentiated in the protein-protein interaction (PPI) network. These hub genes were typically down-regulated. Additionally, DEGs-transcription factors (TFs) connections (e.g. GATA2, YY1 and FOXC1), DEG-microRNA (miRNA) interactions (e.g. hsa-miR-124-3p and has-miR-26b-5p) were also comprehensively forecast. Additionally, related gene ontology concepts (e.g. sequence-specific DNA binding and TF activity) connected to DEGs in HD were identified using gene set enrichment analysis (GSEA). Finally, in silico drug design was employed to find candidate drugs for the treatment HD, and while the possible modest therapeutic compounds (e.g. cortistatin A, 13,16-Epoxy-25-hydroxy-17-cheilanthen-19,25-olide, Hecogenin) against HD were expected. Consequently, the results from this study may give researchers useful resources for the experimental validation of Huntington's diagnosis and therapeutic approaches.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
